Colorectal cancer (CRC) is the second‑leading cause of cancer-related mortality worldwide. It is frequently characterized by chemotherapy resistance，which is a predominant factor contributing to unfavorable patient prognosis. B7-H3 is a novel tumor marker and a potential immunotherapy target. High B7-H3 expression in colorectal cancer is associated with adverse prognosis. In this study, we noted increased B7-H3 expression in colorectal cancer tumor tissues. Both in vivo and in vitro experiments demonstrated that increased B7-H3 expression promotes resistance to chemotherapy in CRC. Furthermore, our findings suggest that B7-H3 mediates CRC resistance by modulating CYP1B1 expression. Mechanistic investigations indicated that B7-H3 inhibited the ubiquitination of CYP1B1, stabilized its expression，and consequently enhanced chemotherapeutic resistance in CRC. In summary, our results underscore the significance of the B7-H3-CYP1B1 interaction as a crucial therapeutic target for overcoming chemotherapy resistance in CRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbadis.2025.167771 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
Cancer
March 2025
Department of Oncology, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan, USA.
Background: Prior studies of participants with breast and other obesity-associated cancers in the Women's Health Initiative (WHI) showed worse mortality and cardiovascular disease (CVD) outcomes for individuals with a higher number of cardiometabolic risk factors at study entry. The purpose of this analysis is to compare the relationship between cardiometabolic abnormalities and mortality among women with and without cancer in the WHI.
Methods: Women with one of five early-stage obesity-associated cancers (breast, colorectal, endometrial, ovarian, and non-Hodgkin lymphoma) and controls without any new or prior history of cancer were selected from the WHI-Life and Longevity after Cancer ancillary study.
Early Recurrence of Colorectal Liver Metastasis (Number ≤ 5 and Largest Diameter ≤ 3 cm) after Resection or Thermal Ablation: a Multi-center Study of Patterns, Safety, Survival and Risk Factors.
J Gastrointest Cancer
March 2025
Department of Interventional Therapy, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Objective: To compare early recurrence patterns, safety, survival and investigate the clinical risk factors of early recurrence (ER) after liver resection or thermal ablation (TA) for patients with colorectal liver metastases (CRLM) with number ≤ 5 and largest diameter ≤ 3 cm.
Materials And Methods: This retrospective study included patients with CRLM who underwent liver resection or TA between January 2016 and December 2021 at two hospitals in China. The Kaplan-Meier method and log-rank test were used to assess recurrence-free survival (RFS) and overall survival (OS).
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature.
Cancer Chemother Pharmacol
March 2025
Medical Oncology, Department of Clinical and Molecular Sciences, University Politecnica delle Marche, Ancona, 60126, Italy.
In recent years, assessing dihydropyrimidine dehydrogenase (DPD) activity has become crucial for cancer patients undergoing 5-fluorouracil (5FU)-based chemotherapy due to the life-threatening toxicity associated with reduced DPD function. The methods for evaluating DPD activity have evolved, with the analysis of DPYD polymorphisms in blood samples becoming the preferred approach. As the indications for liver transplantation are increasing-particularly due to a rise in cases of cholangiocarcinoma (CCA) and non-resectable colorectal liver metastasis-more cancer patients with a history of liver transplantation may experience disease relapse.
View Article and Find Full Text PDFEvaluating organ preservation strategies versus radical surgery in T2N0 rectal cancer: survival outcomes and tumor size impact.
Int J Colorectal Dis
March 2025
The Second Xiangya Hospital, Central South University, Changsha, China.
Preparation of capecitabine-poly(p-dioxanone) electrospraying nanoparticles and influence of particle size on their colorectal cancer inhibitive efficiency.
J Biomater Appl
March 2025
Department of Chemistry, School of Pharmacy, North Sichuan Medical College, Nanchong, China.
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. Capecitabine is a chemotherapeutic agent commonly used for the treatment of colon cancer. To realize local sustained release, promote efficient local intracellular transport, and mitigate the systemic toxic effects of capecitabine, a capecitabine prodrug, capecitabine-poly (p-dioxanone) (Cap-PPDO), was successfully synthesized.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!